Latest Breaking News On - Dystrophy type - Page 1 : comparemela.com

Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints

- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - - DYNE-101 Showed Improvement in Myotonia,.

United statesStacy nartkerWildon farwellAmy reillyJohn coxExchange commissionDrug administrationMyotonic dystrophy health indexEuropean medicines agencyDyne therapeutics incDose dependentMean splicing correction across all patientsMuscle strengthTimed function testsReported outcomesMean unadjusted

Dyne Therapeutics Announces New Clinical Data from ACHIEVE

- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - .

United statesAmy reillyJohn coxStacy nartkerWildon farwellExchange commissionDyne therapeutics incEuropean medicines agencyDrug administrationMyotonic dystrophy health indexDose dependentMean splicing correction across all patientsMuscle strengthTimed function testsReported outcomesMean unadjusted

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesSaudi arabiaCity ofUnited kingdomKingdom of saudi arabiaGreat britainReshma kewalramaniExchange commissionHealthcare products regulatory agencyCompanies to workEuropean medicines agencyHealth canadaVertex pharmaceuticals incorporated nasdaqVertex pharmaceuticals incorporatedHealthcare conferenceChief executive officer

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

BOSTON, January 07, 2024 Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 11:15 a.m. ET/8:15 a.m. PT.

Saudi arabiaUnited statesUnited kingdomCity ofKingdom of saudi arabiaGreat britainHeather nicholsReshma kewalramaniCompanies to workEuropean medicines agencyVertex pharmaceuticals incorporated nasdaqExchange commissionVertex pharmaceuticals incorporatedHealthcare products regulatory agencyHealth canadaHealthcare conference

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomUnited statesSaudi arabiaKingdom of saudi arabiaGreat britainHeather nicholsReshma kewalramaniCompanies to workVertex pharmaceuticals incorporatedHealthcare products regulatory agencyHealth canadaEuropean medicines agencyExchange commissionVertex pharmaceuticals incorporated nasdaqPharmaceuticals incorporated